Monoclonal antibody · Immune activation, directed at B7-H4 (VTCN1) · developed by NextCure
NC762 is a humanized IgG1 kappa monoclonal antibody that binds B7-H4 on the surface of tumor cells. Its Fc region carries three point mutations that enhance binding to CD16a on natural killer cells, increasing antibody-dependent cellular cytotoxicity against B7-H4-expressing cells. It is studied in advanced or metastatic solid tumors, ovarian cancer, non-small cell lung cancer and breast cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04875806 | Phase 1/2 | Advanced or Metastatic Solid Tumors | Terminated | NXTC |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced or Metastatic Solid TumorsBreast CancerNon-small Cell Lung CancerOvarian Cancer
Updated Oct 25, 2026. Something wrong or missing? Report it on the NXTC page.
See NXTC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NXTC catalysts and pipeline →